Verastem, Inc. (VSTM)
8.41
-0.97
(-10.34%)
USD |
NASDAQ |
Nov 06, 16:00
8.31
-0.10
(-1.19%)
After-Hours: 20:00
Verastem Enterprise Value : 708.93M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 708.93M |
| November 05, 2026 | 796.69M |
| November 04, 2026 | 839.22M |
| November 03, 2026 | 831.98M |
| November 02, 2026 | 815.70M |
| October 30, 2026 | 830.17M |
| October 29, 2026 | 822.03M |
| October 28, 2026 | 837.86M |
| October 27, 2026 | 861.84M |
| October 26, 2026 | 852.79M |
| October 23, 2026 | 856.41M |
| October 22, 2026 | 858.22M |
| October 21, 2026 | 781.31M |
| October 20, 2026 | 793.08M |
| October 19, 2026 | 727.93M |
| October 16, 2026 | 730.64M |
| October 15, 2026 | 783.12M |
| October 14, 2026 | 645.59M |
| October 13, 2026 | 622.06M |
| October 12, 2026 | 694.45M |
| October 09, 2026 | 706.21M |
| October 08, 2026 | 681.78M |
| October 07, 2026 | 695.81M |
| October 06, 2026 | 649.21M |
| October 05, 2026 | 671.83M |
| Date | Value |
|---|---|
| October 02, 2026 | 644.69M |
| October 01, 2026 | 662.78M |
| September 30, 2026 | 676.35M |
| September 29, 2026 | 664.59M |
| September 28, 2026 | 651.02M |
| September 25, 2026 | 648.30M |
| September 24, 2026 | 653.73M |
| September 23, 2026 | 688.12M |
| September 22, 2026 | 705.31M |
| September 21, 2026 | 670.92M |
| September 18, 2026 | 621.16M |
| September 17, 2026 | 631.11M |
| September 16, 2026 | 610.30M |
| September 15, 2026 | 612.11M |
| September 14, 2026 | 627.49M |
| September 11, 2026 | 610.30M |
| September 10, 2026 | 637.45M |
| September 09, 2026 | 666.40M |
| September 08, 2026 | 679.07M |
| September 04, 2026 | 689.93M |
| September 03, 2026 | 670.02M |
| September 02, 2026 | 673.64M |
| September 01, 2026 | 636.54M |
| August 31, 2026 | 601.25M |
| August 28, 2026 | 601.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 7.614B |
| Inovio Pharmaceuticals, Inc. | 71.37M |
| Rigel Pharmaceuticals, Inc. | 684.25M |
| United Therapeutics Corp. | 21.75B |
| SELLAS Life Sciences Group, Inc. | 1.562B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.67M |
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 74.75M |
| EPS Diluted (Quarterly) | -0.3463 |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -86.51% |
| Earnings Yield | -29.25% |
| Normalized Earnings Yield | -23.84 |